John Cush/sgu.edu
Aug 27, 2026, 00:04
John Cush: Registry Study Confirms Real-World Liver Risks with Avacopan
John Cush, Editor and CEO RheumNow.com, shared a post on X:
“Registry Data Shows Liver Risk With Avacopan
A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull from the U.S. market.”
Stay updated with Hemostasis Today.
-
Aug 27, 2026, 00:14Join EHA ReCon 2027 in Malta – Explore RNA Biology to Therapeutics
-
Aug 26, 2026, 23:57N. Mariana S. Vasquez: TTP vs ITP vs DIC
-
Aug 26, 2026, 23:49Mauricio Ambriz: Pathogenesis of Autoimmune Hemolytic Anemia Mediated by Warm and Cold Antibodies
-
Aug 26, 2026, 23:45Can Thromboinflammation Biomarkers Improve PE Mortality Prediction? – RPTH Journal
-
Aug 26, 2026, 23:44From Almost Universally Fatal to Largely Treatable iTTP – American Society of Hematology
-
Aug 26, 2026, 23:39Eric Topol: Shingles Vaccine Associated with 10% Drop in Heart Failure and Stroke
-
Aug 26, 2026, 22:59Debbe McCall: Should Frail Elderly Patients Stable on Warfarin Switch to DOACs?
-
Aug 26, 2026, 18:38Maia Meier: Muhiba’s Story of Courage, Resilience and Hope With Type 3 VWD
-
Aug 26, 2026, 18:27Isabella Presch: Not Every Genome-Editing Program Needs to Start From Zero